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Background: The fractional exhaled nitric oxide (FeNO) is a quantitative, noninvasive and safe measure of airways
inflammation that may complement the assessment of asthma. Elevations of FeNO have recently been found to
correlate with allergic sensitization. Therefore, FeNO may be a useful predictor of atopy in the general population.
We sought to determine the diagnostic accuracy of FeNO in predicting atopy in a population-based study.
Methods: We conducted a cross-sectional study in an age- and sex- stratified random sample of 13 to 15 year-olds
in two communities in Peru. We asked participants about asthma symptoms, environmental exposures and
sociodemographics, and underwent spirometry, assessment of FeNO and an allergy skin test. We used multivariable
logistic regression to model the odds of atopy as a function of FeNO, and calculated area-under-the-curves (AUC)
to determine the diagnostic accuracy of FeNO as a predictor of atopy.
Results: Of 1441 recruited participants, 1119 (83%) completed all evaluations. Mean FeNO was 17.6 ppb (SD=0.6) in
atopics and 11.6 ppb (SD=0.8) in non-atopics (p<0.001). In multivariable analyses, a FeNO>20 ppb was associated
with an increase in the odds of atopy in non-asthmatics (OR=5.3, 95% CI 3.3 to 8.5) and asthmatics (OR=16.2, 95%
CI 3.4 to 77.5). A FeNO>20 ppb was the best predictor for atopy with an AUC of 68% (95% CI 64% to 69%).
Stratified by asthma, the AUC was 65% (95% CI 61% to 69%) in non-asthmatics and 82% (95% CI 71% to 91%) in
asthmatics.
Conclusions: FeNO had limited accuracy to identify atopy among the general population; however, it may be a
useful indicator of atopic phenotype among asthmatics.
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The fractional exhaled nitric oxide (FeNO) is a non-
invasive and sensitive biomarker of ongoing eosinophilic
airway inflammation [1,2]. FeNO may be a useful marker
in the assessment of asthma status and control [3,4]. It
has shown potential promise as a non-invasive bio-
marker for asthma because it is a simple, well tolerated
test with no risk to the participant [5] and it provides
real-time, reproducible results in children aged ≥4 years
[1-3,6-9]. For these reasons, FeNO has been recently
recommended as a clinical endpoint for the charac-* Correspondence: wcheckl1@jhmi.edu
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reproduction in any medium, provided the orterization of study populations, in clinical trials and ob-
servational studies [10]. Recent studies, however, have
reported high levels of FeNO even in well-controlled
asthma [1,6,11], indicating that other factors may play a
role in the determination of FeNO levels [12-15]. One
potential factor that could explain variability in FeNO
levels is atopic status.
Atopy is a clinical definition for an IgE-antibody re-
sponder, i.e., a personal tendency to become sensitized
and produce IgE antibodies in response to allergens.
Atopic individuals have an increased risk of developing
asthma and other allergic diseases [16]. The definition of
atopy, however, should only be considered when there is
reported sensitization to allergen-specific IgE antibodies
in serum or with a positive skin prick test to a specific
allergen [16]. Recent studies have reported a strongl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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et al. [18] reported a positive correlation between FeNO
and the number of positive skin prick tests in a cohort
of asthmatics. Previous studies have also correlated
aeroallergen sensitization with FeNO levels in atopic chil-
dren [7,13,16,19,20]. These findings underscore the rele-
vance of evaluating allergen sensitization status when
FeNO is used as a biomarker in the diagnosis and moni-
toring of asthma [18]. More importantly, it also supports
the hypothesis that FeNO may serve as a biomarker of
atopy. The fact that atopy cannot always be identified
using an allergy skin test [21], and the underlying risks in-
volved in the determination of allergic skin sensitization
increases the importance of studying the validity of FeNO
as a simple, non-invasive biomarker for atopy [2,4,17].
The presence of a low to normal FeNO level in patients
with chronic respiratory symptoms could also be helpful
to rule out atopic status [20,22], however, there is a lack of
strong evidence to support the role of FeNO in identifying
atopy [2,5,11,23-25]. One recent study by Yao et al.
reported that FeNO was a better marker of allergic
sensitization than it was of asthma [17]. In this study, we
seek to determine the clinical utility of FeNO as a non-
invasive marker of atopy in a population-based study.Methods
Study design
The study design is described in detail elsewhere [26]. We
conducted a cross-sectional study of asthma prevalence in
two regions in Peru. In December 2008, we selected a ran-
dom sample of children aged 13 to 15 years from commu-
nity censuses and visited them for enrollment into the
study between April 2009 and December 2010. We asked
participants about asthma and allergy symptoms, socio-
demographics and environmental exposures, obtained
anthropometry and a blood sample, and conducted an
allergy skin test, a FeNO test and spirometry before and
after bronchodilators. We used a previously validated
Spanish version of the ISAAC questionnaire [13]. This
study was approved by the Institutional Review Boards of
the Johns Hopkins Bloomberg School of Public Health
(Baltimore, USA) and A.B. PRISMA (Lima, Peru).FeNO assessment
We measured FeNO using a portable chemilumines-
cence analyzer (NIOXMINO, Aerocrine, Solna, Sweden)
according to joint ERS/ATS recommendations [4,25].
No assessments were made if a participant reported a re-
spiratory infection in the last 2 weeks or if the partici-
pant was on oral corticosteroids. We categorized FeNO
levels using cut-off values of <20 ppb, 20-35 ppb and >35
ppb, respectively [25].Assessment of atopy
Allergy skin tests were performed using the Multi-Test
II system (Lincoln Diagnostics, Decatur, IL) with allergen
extracts made by ALK-Abello (Round Rock, TX). We
used 10 allergens in the assessment: cockroach (Blattella
germanica), dust mite mix (Dermatophagoides farinae
and D. pteronyssinus), cat hair, dog epithelium, mouse
epithelium, and mixed molds (Alternaria, Cladosporium,
mixed Aspergillus, and mixed Penicillium). We also
applied a histamine solution (10mg/ml) as a positive
control and saline (0.9%) as a negative control. As per
manufacturer’s instructions, we recorded vertical and
horizontal measurements of induration and erythema,
alongside 0–2 scales of itchiness and pseudopodia 20
minutes after application. Atopy was defined as a posi-
tive skin response to any of the allergen specificities as
previously described [16,20,26].
Definitions
We defined current asthma symptoms as wheeze or use
of asthma medications in the past 12 months; allergic
rhinitis as nasal symptoms (i.e., rhinorrhea, nasal dis-
charge, nasal obstruction or nasal-ocular pruritus) with-
out cold or flu symptoms in the past 12 months; and,
smoking as self-reported tobacco use. We defined aller-
gic symptoms if a child had either asthma symptoms or
allergic rhinitis in the past 12 months. We calculated
body mass index (BMI) percentile according to World
Health Organization reference values [27]. We classified
underweight as <5th percentile; normal as 5th to 84th
percentiles; overweight as 85th to 94th percentiles, and
obese as ≥95th percentile for their age and sex. We
defined current inhaled corticosteroid use if the child
used it in the last week.
Biostatistical methods
We compared continuous variables between two sub-
groups with t-tests if normally distributed and with
Wilcoxon rank-sum tests if not normally distributed, and
compared dichotomous or categorical values between two
subgroups with chi-square tests. We used multiple linear
regression to identify risk factors associated with log-
transformed FeNO in our study population. We used
multiple logistic regression to estimate the odds of atopy
for FeNO first as a continuous variable and then as a cat-
egorical variable using the above defined cut-offs, adjusted
for sex, allergy symptoms, BMI, personal history of to-
bacco use, secondhand smoke, seasonality and site. We
excluded current use of inhaled corticosteroids as a covari-
ate because only 2 participants reported such intake. To
assess the diagnostic accuracy of FeNO to predict atopy,
we constructed receiver-operating-characteristic (ROC)
curves and calculated the areas-under-the-curve (AUC)
using five-fold cross validation [28]. We also conduced
Table 1 Study Characteristics
Variable Children with FeNO and atopy data Children with incomplete data P
Sample size 1199 242
Male, % (n) 52% (622) 52% (125) 0.95
Age, mean (range) 14.9 (12.2-16.6) 14.8 (13.3-16.5) 0.43
Height in cm, mean (SD) 158.5 (8.2) 156.9 (7.4) 0.05
Current Asthma, % (n) 7% (89) 7.0% (17) 0.83
Allergic rhinitis, % (n) 17% (201) 21% (51) 0.11
Rural, % (n) 52% (625) 38% (91) 0.001
BMI, mean (range) 21.1 (13.9 – 39.2) 21.8 (15.1 – 36.6) 0.06
Secondhand smoke, % (n) 19% (232) 19% (46) 0.91
History of tobacco use, % (n) 5% (54) 4% (4) 0.59
Table 2 Single variable and multivariable analyses of factors associated with Fractional exhaled nitric oxide (FeNO)
Fractional exhaled nitric oxide in ppb
n Geometric mean (SD) P Coefficient in log ppb P
Sex
Male 622 15.8 (0.7) <0.001 Reference
Female 577 12.4 (0.7) −0.22 <0.001
Atopy
Yes 556 17.6 (0.6) <0.001 0.36 <0.001
No 643 11.6 (0.8) Reference
Current asthma
Yes 89 27.9 (1.0) <0.001 0.48 <0.001
No 1110 13.3 (0.7) Reference
Allergic Rhinitis
Yes 201 21.8 (0.9) <0.001 0.31 <0.001
No 998 12.8 (0.7) Reference
Season of FeNO measurement
Fall 236 18.9 (21.6) <0.01 Reference
Winter 424 19.1 (22.9) 0.11 0.07
Spring 451 20.0 (23.3) 0.20 <0.001
Summer 88 23.1 (20.9) 0.23 0.01
Site
Lima 574 15.6 (0.8) <0.001 Reference
Tumbes 625 12.4 (0.7) −0.01 0.74
Personal history of tobacco smoke
Yes 54 18.1 (0.8) <0.01
No 1086 14.1 (0.7) 0.12 0.20
Body mass index (kg/m2)
Low weight 18 17.2 (15.9) 0.15 Reference
Normal 936 18.9 (21.1) 0.01 0.93
Overweight 212 22.9 (23.2) 0.14 0.48
Obese 33 22.8 (28.7) 0.04 0.80
Second hand smoke
Yes 232 14.3 (0.7) 0.11 −0.07 0.20
No 967 13.1 (0.8) Reference
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Table 3 Multivariable analyses of predictors of atopy in 1199 Peruvian children
Variable Crude Odds ratio p-value Adjusted Odds Ratio (95% CI) p-value
Fractional exhaled nitric oxide
>35 ppb 6.7 <0.001 5.6 (3.7-8.8) <0.001
20-35 ppb 2.5 <0.001 2.2 (1.5-3.2) <0.001
<20 ppb 1.0 Reference
Site (rural) 0.5 <0.001 0.4 (0.3-0.6) <0.001
Season of Fractional exhaled nitric oxide measurement
Fall 1.0 Reference
Winter 0.5 <0.001 0.3 (0.2-0.5) <0.001
Spring 0.4 <0.001 0.2 (0.2-0.4) <0.001
Summer 1.1 0.861 0.4 (0.3-0.8) <0.001
Allergy Symptoms 2.3 <0.001 1.5 (1.1-2.0) 0.03
Body mass index 1.1 0.01 1.0 (1.0-1.1) 0.27
Personal smoke 1.5 0.17 1.1 (0.6-2.0) 0.82
Second hand smoke 1.1 0.62 1.1 (0.8-1.6) 0.41
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conducted statistical analyses in STATA 11 (STATA Corp.,
College Station, USA).
Results
Characteristics of the study population
Of 1441 enrolled participants, 1199 (83%) completed
both FeNO and allergy skin test assessments. We did
not observe major differences between those with and
without incomplete assessments (Table 1); however, we
were more successful in obtaining both FeNO and an
allergy skin tests among participants in Tumbes vs. Lima
(p<0.001). Of the 1199 children with complete measure-
ments, 52% were male, mean age was 14.9 years
(SD=0.9), 21% were overweight, the prevalence of atopy
was 46% based on skin test results and mean FeNO was
19.7 ppb (SD=22.6).
Factors associated with FeNO
Boys had higher FeNO levels than girls (15.8 ppb vs.
12.4 ppb; p<0.001). Children in Lima had higher FeNO
levels than those in Tumbes (15.6 vs. 12.8 ppb; p<0.001).
Mean FeNO was higher in atopics than in non-atopics
(17.6 ppb vs. 11.6 ppb; p<0.001), higher in asthmatics
than in non-asthmatics (27.9 ppb vs. 13.3 ppb; p<0.001)Table 4 Diagnostic accuracy of Fractional exhaled nitric oxide
Sensitivity % Specificity %
FeNO > 20 ppb 47.8 81.5
FeNO > 25 ppb 52.2 71.7
FeNO > 35 ppb 47.1 74.7
By asthma status (FeNO > 20 ppb)
Non-asthmatics 37.7 84.8
Asthmatics 87.5 52.0and higher in participants with allergic rhinitis compared
to those without (21.8 ppb vs. 12.8; ppb p<0.001). FeNO
also varied with season and personal history of tobacco
use (all p<0.01). We did not find statistically significant
differences in FeNO levels with tobacco smoke exposure,
either personal or secondhand smoke or BMI categories
(Table 2). In multiple linear regression with log FeNO as
the outcome, important associations remained with
atopy, current asthma symptoms, rhinitis and sex
(p<0.001).Predictors of atopy
In multivariable logistic regression, the odds of atopy in-
creased with higher FeNO levels and with allergic symp-
toms, and was lower among children living in Tumbes vs.
Lima (Table 3). We identified a dose–response relation-
ship between FeNO and atopy (p<0.001). Having a
FeNO>35 ppb was associated with atopy in children after
adjusting for sex, height, BMI, site, allergy symptoms, per-
sonal history of tobacco, second hand smoke exposure
and season of FeNO measurement (adjusted OR=5.6, 95%
CI 3.6 to 8.8; p<0.001). FeNO levels 20–35 ppb were also
associated with an increased odds of atopy (adjusted
OR=2.2, 95% CI 1.5 to 3.1, p<0.001).(FeNO) for atopy
PPV % NPV % AUC% (95% CI)
69.1 64.4 68 (64–69)
61.4 63.4 67 (64–70)
61.7 62.0 66 (63–69)
66.1 62.9 65 (61–69)
82.4 61.9 82 (71–91)
Figure 1 ROC Curve indicating the sensitivity and specificity of
Fractional exhaled nitric oxide (FeNO) to predict atopy
(FeNO > 20 ppb).
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We evaluated three different cut-off values of FeNO in
relation to atopy, and found that FeNO>20 ppb was the
best predictor for atopy (Table 4). Estimated AUC was
68% (95% CI 64% to 69%) after adjusting by sex, BMI,
asthma, rhinitis and season of FeNO measurement
(Figure 1). We observed better discrimination in specific
subgroups. The AUC in non-asthmatics was only 65%
(95% CI 61% to 69%), whereas it increased to 82% (95%
CI 71% to 91%) in asthmatics (Figure 2). We also found
that the AUC was 74% (95% CI 65% to 80%) and 66%
(95% CI 62% to 70%) among those with and without al-
lergic rhinitis, respectively.
We found that there was gradient between the number
of positive reactions and the prevalence of atopy. Specif-
ically, mean FeNO for non-atopics was 14.2 ppb
(SD=13.3); 17.0 ppb for atopics with 1 positive reaction
(SD=15.4); 29.2 ppb (SD=33.0) for atopics with 2 posi-
tive reactions; and, 33.9 ppb (SD=33.6) for atopics with
≥3 positive reactions (p<0.001). The AUC increased
from to 67% (95% CI 64% to 71%) to 73% (95% CI 70%
to 76%) if we considered atopy in participants with ≥2
positive skin tests. Using similar analytical methods, weFigure 2 ROC Curve indicating the accuracy of Fractional exhaled nitr
(FeNO > 20ppb).evaluated the same three FeNO cut-offs in relation to
current asthma symptoms, and found that a FeNO>35
ppb had a AUC of 80% (95% CI 74% to 85%).
Discussion
Our results suggest that FeNO had a modest ability to
identify either atopy alone or asthma alone in our study
population; however, our data suggest that it may be a
useful aid in differentiating between atopic and non-
atopic phenotypes among asthmatic children. We found
that a FeNO>20 ppb may have sufficient discriminatory
power to identify the asthmatic atopic phenotype.
Our results showed that FeNO had limited accuracy in
identifying atopy in the general population. These
findings contrast with those reported by Yao et al. [17],
who reported a better discrimination of FeNO for aller-
gic sensitization in the general population than that
reported by our group (AUC of 80%, 95% CI 77% to
82%). Differences between the study conducted by Yao
et al. and our current study could be attributed to the
target population and assessment of atopy. Previous
studies have described that age contributes to the vari-
ability of FeNO [4,5,8,18,20,25]. Our study had an older
but narrower age range than the study by Yao et al.
(5–18 years). Other studies suggest that FeNO may be
more useful in young children, who often have no cor-
relation with spirometric assessments or the manifest-
ation of symptoms, but in whom a screening, early
diagnosis, and preventive measures would be useful
[19,20]. Other differences included the method of atopic
assessment. Yao et al. conducted atopic assessment
using the multi-allergen screen for serum specific IgE
(e.g. Phadiatop), whereas we used allergy skin testing.
Because allergy skin prick testing does not always iden-
tify atopy accurately, measurement of a panel of serum
specific IgE is the best method to assess atopy. Some
studies report a concordance between 85% and 95%,
depending on the allergen being tested, between allergy
skin testing and measurement of serum specific IgE [29];ic oxide (FeNO)measurements to predict atopy by asthma
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interchangeably to determine atopic sensitization or if
both should be used for the diagnosis of atopy [29-31].
Finally, another difference between both studies were
that the study by Yao et al. and ours used different
chemiluminescence analyzers for FeNO.
Variables such as sex, current asthma, allergic rhinitis,
personal history of tobacco use, current use of inhaled
corticosteroids, atopy and seasonality have all been pre-
viously identified as important explanatory factors that
influence FeNO levels [17,20,24,32]. While our study
corroborates the importance of these variables in our
study setting, we also found that rural dwelling (i.e., liv-
ing in Tumbes vs. Lima) was additional important
explanatory factor associated with FeNO levels. Indeed,
few studies have considered the rural versus urban
setting in their analysis or study design, despite
well-recognized differences in the prevalence of asthma
and allergic disease between these two environments
[26,33,34]. This is particularly relevant to investigations
in low- and middle-income countries, as two recent
studies conducted in South America, one in Ecuador
[33] and another conducted by our team in Peru [26]
have shown that urbanization increases the risk of both
asthma and allergic diseases. The differences in FeNO
levels are explained by the higher prevalence and in-
creased severity of both asthma and atopy in Lima com-
pared to Tumbes [26]. Use of tobacco could impact
assessment of FeNO, and if under-reported, could have
affected our results. We found an overall low prevalence
of daily smokers in previous surveys of tobacco use in our
study population. Using a previously-validated, Spanish
questionnaires of tobacco smoke in the region, our group
reported a low prevalence of daily smoking in adults [35].
Our findings may help to explain previous inconsis-
tences that other studies have reported when using
FeNO levels as a criterion in the diagnosis or ma-
nagement of asthma [6,8,12,15,22,23]. We found that
FeNO>35 ppb predicted asthma with better accuracy
than cutoffs of 20 ppb or 25 ppb. This points to the
importance of proper characterization of the atopic
phenotype when interpreting the relationship between
FeNO and asthma, and also the proper consideration of
particular cut-off FeNO values by atopic status, age and
sex. Another explanation for previous inconsistences
with other studies using FeNO levels could be related to
methodology mostly related to flow dependence and
the type of device used to measure FeNO. Recently,
Malinovschi et al. [36] compared several methods of
measuring FeNO and found a better association between
asthma control using exhaled breath condensate nitrates
rather than with chemiluminescence analyzers for FeNO,
which is currently considered the gold standard
[25,36,37].Our study has some potential shortcomings. First, our
findings are cross-sectional and we do not evaluate lon-
gitudinal changes in FeNO values within individuals.
Studies have reported different coefficient of variations
from 10% (about 4ppb) in healthy individuals to 40% in
asthmatics [10-12]. Second, we assessed only at a narrow
age range, and predictive cut-offs may change with age.
Future investigations should include younger children or
cover a broad age range, consider within-individual
changes in FeNO levels and assessment of environmen-
tal allergenic exposures [10,21,25,34,37]. Third, we mea-
sured atopic sensitization to indoor aeroallergens only
and did not include pollen or food allergens.
We chose not to measure pollens because Lima is lo-
cated in a semi-arid, tropical region where there are few
tree and grass allergens. While it is possible that food al-
lergy may affect our overall prevalence of atopy and po-
tentially the values of fractional exhaled nitric oxide
[38]; however, the incidence of food allergies in our
study population is unknown and understudied. Fourth,
we did not conduct an evaluation of parasitic infections
in our study children; however, previous population-
based evaluations by our team on the burden of soil-
based helminths in our study areas have been previously
found to be low [39]. Finally, another aspect to consider
is that potential genetic differences may exist between
our study sites, which were settled by different ethnic
groups; despite that phenotypically, these populations
are similar (i.e., mestizo).Conclusion
In summary, our data suggest that FeNO had modest
discriminatory power to identify atopy among the gen-
eral population. It appeared to be a more useful tool to
identify atopic phenotype among asthmatics. If this find-
ing is further validated, FeNO may provide a simple,
real-time non-invasive screen for atopy among asth-
matics especially in resource-poor countries with limited
access to medical specialists.
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